Supply of Sodium Nitroprusside (Commercial Pharmaceutical Product)

The contract mandates the manufacture and delivery of sterile Sodium Nitroprusside, USP in 2 mL vials, meeting stringent quality standards set by the FDA, USP, and military labeling requirements to ensure suitability for critical care environments. The product must be produced in compliance with current Good Manufacturing Practices and validated for sterility, potency, and stability, with packaging and labeling adhering to all federal and defense-specific regulations for distribution to military and federal healthcare facilities. The solicitation, issued under the Department of Defense’s Medical Supply Chain Pharma FSA, is classified as a subcontract with NAICS code 325412, indicating it targets pharmaceutical manufacturing. The opportunity was posted on May 10, 2026, with responses due by May 18, 2026, and performance is expected to support the defense medical logistics network without geographic constraints specified. All deliverables must be fully traceable, documented, and conform to the military’s supply chain integrity protocols to ensure reliability and regulatory compliance in high-acuity clinical settings.